Abstract
We tested specific gene polymorphisms known to be involved in the irinotecan (CPT-11) metabolic pathway. The combination of at least one SLCO1B1 521 T allele, one ABCB1 1236 C allele and one UGT1A1*28 variant 7 repeat demonstrated a statistically significant association with Grade 3/4 toxicities in metastatic colorectal cancer patients.
Keywords: Polymorphisms, colorectal cancer, toxicity, irinotecan
Drug Metabolism Letters
Title: ABCB1, SLCO1B1 and UGT1A1 Gene Polymorphisms Are Associated with Toxicity Line Irinotecan
Volume: 1 Issue: 1
Author(s): Katrin E. Rhodes, Wu Zhang, Dongyun Yang, Oliver A. Press, Michael Gordon, Daniel Vallbohmer, Anne M. Schultheis, Georg Lurje, Robert D. Ladner, William Fazzone, Heinz-Josef Lenz and Syma Iqbal
Affiliation:
Keywords: Polymorphisms, colorectal cancer, toxicity, irinotecan
Abstract: We tested specific gene polymorphisms known to be involved in the irinotecan (CPT-11) metabolic pathway. The combination of at least one SLCO1B1 521 T allele, one ABCB1 1236 C allele and one UGT1A1*28 variant 7 repeat demonstrated a statistically significant association with Grade 3/4 toxicities in metastatic colorectal cancer patients.
Export Options
About this article
Cite this article as:
Rhodes E. Katrin, Zhang Wu, Yang Dongyun, Press A. Oliver, Gordon Michael, Vallbohmer Daniel, Schultheis M. Anne, Lurje Georg, Ladner D. Robert, Fazzone William, Lenz Heinz-Josef and Iqbal Syma, ABCB1, SLCO1B1 and UGT1A1 Gene Polymorphisms Are Associated with Toxicity Line Irinotecan, Drug Metabolism Letters 2007; 1 (1) . https://dx.doi.org/10.2174/187231207779814328
DOI https://dx.doi.org/10.2174/187231207779814328 |
Print ISSN 1872-3128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-0758 |
Related Articles
-
Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
Current Pharmaceutical Design Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Recent Developments in Tumor Angiogenesis
Current Pharmaceutical Biotechnology Ovarian Hyperstimulation Syndrome: The Best Approaches for Preven-tion and Treatment: A Mini-Review
Current Women`s Health Reviews Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry In Vitro Anticancer Evaluation of Platinum(II/IV) Complexes with Diisoamyl Ester of (S,S)-ethylenediamine-N,N’-di-2-propanoic Acid
Anti-Cancer Agents in Medicinal Chemistry Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery Erythropoietin in Cancer: An Update
Current Molecular Medicine Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Molecular Mistletoe Therapy: Friend or Foe in Established Anti-Tumor Protocols? A Multicenter, Controlled, Retrospective Pharmaco-Epidemiological Study in Pancreas Cancer
Current Molecular Medicine Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine The Role of Reactive Oxygen Species in Tumor Treatment and its Impact on Bone Marrow Hematopoiesis
Current Drug Targets Urtica dioica Extract Inhibits Cell Proliferation and Induces Apoptosis in HepG2 and HTC116 as Gastrointestinal Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Molecular and Metabolic Imaging of Hepatic Neuroendocrine Tumors Following Radioembolization with 90Y-microspheres
Current Medical Imaging